Ilyang discontinues licensing-out negotiation over ilaprazole

Ilyang Pharmaceutical Co. said in a regulatory filing, Thursday, that it has suspended the negotiation of a licensing-out deal with one of multinational drug makers over ilaprazole, a new investigational proton pump inhibitor (PPI) used in the treatment of dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD) and duodenal ulcer.

The company did not disclose the d...